AI Score

Unlock

Becton Dickinson and (BDX)

AI Score

Unlock

200.40

0.00 (0.00%)

At close: Apr 17, 2025, 11:38 AM

0.00% (1D)

Bid	200.2
Market Cap	57.54B
Revenue (ttm)	20.64B
Net Income (ttm)	1.73B
EPS (ttm)	5.93
PE Ratio (ttm)	33.79
Forward PE	12.92
Analyst	Buy

Ask	200.51
Volume	1,571,856
Avg. Volume (20D)	2,145,980
Open	199.50
Previous Close	200.40
Day's Range	198.73 - 200.84
52-Week Range	193.03 - 251.99
Beta	0.38

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and pr...

Sector Healthcare

IPO Date Feb 21, 1973

Employees 70,000

Stock Exchange NYSE

Ticker Symbol BDX

Website https://www.bd.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for BDX stock is "Buy." The 12-month stock price forecast is $275, which is an increase of 37.23% from the latest price.

Stock Forecasts

Next Earnings Release

Becton Dickinson and is scheduled to release its earnings on May 1, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-7.28%

Becton, Dickinson and Company shares are trading l... Unlock content with Pro Subscription

2 months ago

+1.09%

Becton, Dickinson and Company shares are trading lower following Q1 financial results.

News

1 week ago · zacks.com

BD Seeks Potential Buyers for Life Sciences Business Division

Becton Dickinson is in preliminary talks to divest its $21 billion Life Sciences unit, exploring multiple options with major medtech players and diagnostics firms.

2 weeks ago · reuters.com

Becton Dickinson in talks to divest life sciences unit, FT reports

Medical device maker Becton Dickinson has begun discussions to sell its life sciences division, valued at $21 billion, and is in talks with competitors such as Thermo Fisher Scientific and Danaher , t...

2 weeks ago · seekingalpha.com

Best Dividend Aristocrats For April 2025

Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Br...

2 weeks ago · seekingalpha.com

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Becton Dickinson gets rating buy in my first coverage of this stock. Macro demand for medtech and surgical supplies could favor this globally diversified firm with an active portfolio and growth pipel...

3 weeks ago · zacks.com

BDX Stock Declines Following Class I Classification for Alaris Recall

BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.

3 weeks ago · zacks.com

BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone

BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.

3 weeks ago · seekingalpha.com

2025 Dividend Kings: Strong Run Continues

The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...